SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Biocom, the
association for the California
life science community, issued the statement below following
passage of 21st Century Cures legislation in Congress.
The bill passed in the House on November
30 by a 392-26 vote and in the Senate on December 7 by a 94-5 vote. This statement may be
attributed to Joe Panetta, president
& CEO of Biocom:
"Today, Congress approved historic legislation that will give
hope to millions of patients around the world. The measure
culminates three years of hard work and dedication from government,
industry, the patient community, and many others, all committed to
one goal: finding treatments and cures to the world's most dreaded
diseases. Today, we are one step closer to achieving that goal.
"This landmark legislation addresses some of the most pressing
challenges that currently hinder biomedical innovation and the
development of the next generation of innovative products. The
bill increases funding for research at the National Institutes of
Health (NIH), including for the Precision Medicine Initiative,
Cancer Moonshot Initiative, BRAIN Initiative, and regenerative
medicine. It also makes much needed changes to our regulatory
environment to ensure that patients have access to life-enhancing
and life-saving medicines faster.
"While Biocom had supported additional funding for the NIH, we
applaud this large-scale, bipartisan, and collaborative effort that
will change the future of innovation in the United States. We look forward to working
with the new Administration and Congress over the coming years on
the implementation of the bill and on issues that were not
addressed in the bill, including the reimbursement of telemedicine,
remote patient monitoring services, and other emerging
technologies, that together represent the future of modern
medicine."
About Biocom
Biocom is the largest, most experienced
leader and advocate for California's life science sector. We work on
behalf of more than 800 members to drive public policy, build an
enviable network of industry leaders, create access to capital,
introduce cutting-edge STEM education programs and create robust
value-driven purchasing programs. Founded in 1995 in San Diego, Biocom provides the strongest
public voice to research institutions and companies that fuel the
local and state-wide economy. Our goal is simple: to help our
members produce novel solutions that improve the human condition.
In addition to its San Diego
headquarters, Biocom operates a core office serving the
Los Angeles market, satellite
offices in Washington, D.C. and
Tokyo, and has a continuous staff
presence in Sacramento and
San Francisco. Our broad
membership benefits apply to biotechnology, pharmaceutical, medical
device, genomics and diagnostics companies of all sizes, as well as
to research universities and institutes, clinical research
organizations, investors and service providers. For more
information, visit us at www.biocom.org. Connect with us on
LinkedIn, Facebook, and Twitter (@BIOCOMCA).
Logo -
http://photos.prnewswire.com/prnh/20130228/LA69104LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocom-applauds-passage-of-landmark-biomedical-innovation-legislation-300374769.html
SOURCE Biocom